Fate Therapeutics (FATE) Return on Capital Employed (2013 - 2026)
Fate Therapeutics' (FATE) quarterly Return on Capital Employed came in at 51.4% in Q1 2026, down 20.0% YoY from 64.25% in Q1 2025, and down 2.74% on a QoQ basis from 50.03% in Q4 2025.
Fate Therapeutics (FATE) Return on Capital Employed (2013 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 14 years of Return on Capital Employed data on file, last reported at 51.4% in Q1 2026.
- Quarterly Return on Capital Employed fell 20.0% year-over-year to 51.4% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 51.4% (down 20.0% YoY) and the FY2025 annual result came in at 42.97%, up 538.0% from the prior year.
- Return on Capital Employed fell to 51.4% in Q1 2026, from 50.03% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 30.2% in Q1 2022 to a low of 53.96% in Q2 2025.
- A 5-year average of 44.73% and a median of 43.23% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed tumbled 2654 bps — and 2023, when it soared 1107 bps.
- Tracing FATE's Return on Capital Employed over 5 years: stood at 50.27% in 2022, then advanced by 22 bps to 39.21% in 2023, then dropped by 25 bps to 48.98% in 2024, then slipped by 2 bps to 50.03% in 2025, then dropped by 3 bps to 51.4% in 2026.
- The last three Return on Capital Employed figures came in at 51.4% (Q1 2026), 50.03% (Q4 2025), and 53.02% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | -51.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -51.40% |
| Dec 31, 2025 | -50.03% |
| Sep 30, 2025 | -53.02% |
| Jun 30, 2025 | -53.96% |
| Mar 31, 2025 | -51.21% |
| Dec 31, 2024 | -48.98% |
| Sep 30, 2024 | -41.44% |
| Jun 30, 2024 | -37.99% |
| Mar 31, 2024 | -43.23% |
| Dec 31, 2023 | -39.21% |
| Sep 30, 2023 | -39.56% |
| Jun 30, 2023 | -42.99% |
| Mar 31, 2023 | -42.39% |
| Dec 31, 2022 | -50.27% |
| Sep 30, 2022 | -46.47% |
| Jun 30, 2022 | -37.99% |
| Mar 31, 2022 | -30.20% |
| Dec 31, 2021 | -24.89% |
| Sep 30, 2021 | -19.93% |
| Jun 30, 2021 | -17.06% |